About this Blog

The coronavirus (COVID-19) pandemic has not left any country spared and health systems face challenges on multiple fronts. Cardiovascular disease is the world’s largest cause of morbidity and mortality. It is emerging as a common risk factor at baseline in the individuals most likely to have poor outcomes from COVID-19 infection. There is little yet known about the potential cardiac complications which may occur following COVID-19 infection, and there are many questions to be answered, whether through epidemiology and basic science or trials and pharmacology. In this blog, “The Heart in the Time of COVID-19”, WHF Emerging Leaders combine global perspective with updates of relevant the most recent science relating to cardiovascular disease and COVID-19. We hope this knowledge will be shared widely and together we can learn how to prevent and treat this disease which is truly unprecedented in its scale.

by: Amitava Banerjee and Pablo Perel

Please click here for a table of contents.

Latest from the Blog

Do COVID STEMIs have a higher thrombus burden? More questions & implications

by:Aaysha Cader Whilst much has been written about COVID-19 and its inflammation-thrombosis-hypercoagulability cascade, this has to a large extent focused on venous thromboembolism (VTE). As more data emerges, it is evident that the intense inflammatory response associated with SARS-COV-2 infection may trigger thrombosis across multiple vascular beds, with large thrombus burden in ST-segment elevation myocardialContinue reading “Do COVID STEMIs have a higher thrombus burden? More questions & implications”

Get new content delivered directly to your inbox.